(DHI) DR Horton - Overview
Sector: Consumer Cyclical | Industry: Residential Construction | Exchange: NYSE (USA) | Market Cap: 40.664m USD | Total Return: 22.4% in 12m
Housing, Land, Mortgages, Rentals
Total Rating 44
Safety 37
Buy Signal 0.01
Residential Construction
Industry Rotation: +4.8
Industry Rotation: +4.8
Market Cap:
40.7B
Avg Turnover: 377M USD
Avg Turnover: 377M USD
ATR:
3.52%
Peers RS (IBD): 64.3
Peers RS (IBD): 64.3
Risk 5d forecast
Volatility35.2%
Rel. Tail Risk-7.78%
Reward TTM
Sharpe Ratio0.54
Alpha-3.65
Character TTM
Beta0.725
Beta Downside0.732
Drawdowns 3y
Max DD41.28%
CAGR/Max DD0.35
EPS (Earnings per Share)
EPS CAGR: -16.71%
EPS Trend: -57.2%
EPS Trend: -57.2%
Last SUE: 0.26
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: -3.91%
Rev. Trend: -5.9%
Rev. Trend: -5.9%
Last SUE: 0.64
Qual. Beats: 0
Qual. Beats: 0
Warnings
Beneish M-Score -1.44 > -1.5 - likely earnings manipulation
Tailwinds
No distinct edge detected
Description: DHI DR Horton
D.R. Horton, Inc. (DHI) is a homebuilding company operating across 36 states in the United States. The company acquires and develops land, then constructs and sells residential homes. Homebuilding is a cyclical industry influenced by interest rates and housing demand.
Beyond traditional single-family and attached homes, DHI also offers mortgage financing and title services, which are common ancillary services in the homebuilding sector. They are also involved in multi-family and single-family rental properties, residential lot development, and insurance operations. Additionally, DHI holds water rights and non-residential real estate assets.
To understand DHIs performance metrics and market position, consider exploring its detailed financials on ValueRay.
- Mortgage interest rates directly impact homebuyer affordability and demand
- Land acquisition and development costs influence profitability
- Housing inventory levels affect pricing power and sales volume
- Regulatory changes in zoning and building codes create operational risks
- Economic growth and employment rates drive housing market strength
Piotroski VR‑10 (Strict)
7.0
| Net Income: 3.34b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.88 > 1.0 |
| NWC/Revenue: 76.02% < 20% (prev 85.78%; Δ -9.76% < -1%) |
| CFO/TA 0.10 > 3% & CFO 3.63b > Net Income 3.34b |
| Net Debt (3.04b) to EBITDA (4.46b): 0.68 < 3 |
| Current Ratio: 6.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (293.3m) vs 12m ago -9.40% < -2% |
| Gross Margin: 23.27% > 18% (prev 0.26%; Δ 2.30k% > 0.5%) |
| Asset Turnover: 96.24% > 50% (prev 104.7%; Δ -8.50% > 0%) |
| Interest Coverage Ratio: 139.3 > 6 (EBITDA TTM 4.46b / Interest Expense TTM 31.3m) |
Altman Z''
10.00
| A: 0.74 (Total Current Assets 30.02b - Total Current Liabilities 4.54b) / Total Assets 34.64b |
| B: 0.91 (Retained Earnings 31.50b / Total Assets 34.64b) |
| C: 0.13 (EBIT TTM 4.36b / Avg Total Assets 34.83b) |
| D: 3.12 (Book Value of Equity 31.51b / Total Liabilities 10.08b) |
| Altman-Z'' Score: 11.91 = AAA |
Beneish M
-1.44
| DSRI: 1.33 (Receivables 458.9m/377.8m, Revenue 33.52b/36.69b) |
| GMI: 1.11 (GM 23.27% / 25.73%) |
| AQI: 3.18 (AQ_t 0.12 / AQ_t-1 0.04) |
| SGI: 0.91 (Revenue 33.52b / 36.69b) |
| TATA: -0.01 (NI 3.34b - CFO 3.63b) / TA 34.64b) |
| Beneish M-Score: -1.44 (Cap -4..+1) = D |
What is the price of DHI shares?
As of April 12, 2026, the stock is trading at USD 142.64 with a total of 3,422,114 shares traded.
Over the past week, the price has changed by +0.65%, over one month by -1.82%, over three months by -10.43% and over the past year by +22.44%.
Over the past week, the price has changed by +0.65%, over one month by -1.82%, over three months by -10.43% and over the past year by +22.44%.
Is DHI a buy, sell or hold?
DR Horton has received a consensus analysts rating of 3.62.
Therefor, it is recommend to hold DHI.
- StrongBuy: 6
- Buy: 3
- Hold: 10
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the DHI price?
| Analysts Target Price | 160.1 | 12.3% |
DR Horton (DHI) - Fundamental Data Overview
as of 12 April 2026
P/E Trailing = 12.7106 P/E Forward = 13.3333
P/S = 1.213
P/B = 1.6865
P/EG = 1.1678
Revenue TTM = 33.52b USD
EBIT TTM = 4.36b USD
EBITDA TTM = 4.46b USD
Long Term Debt = 5.55b USD (from longTermDebt, last quarter)
Short Term Debt = 829.0m USD (from shortTermDebt, last quarter)
Debt = 5.55b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.04b USD (from netDebt column, last quarter)
Enterprise Value = 43.70b USD (40.66b + Debt 5.55b - CCE 2.51b)
Interest Coverage Ratio = 139.3 (Ebit TTM 4.36b / Interest Expense TTM 31.3m)
EV/FCF = 12.57x (Enterprise Value 43.70b / FCF TTM 3.48b)
FCF Yield = 7.95% (FCF TTM 3.48b / Enterprise Value 43.70b)
FCF Margin = 10.37% (FCF TTM 3.48b / Revenue TTM 33.52b)
Net Margin = 9.95% (Net Income TTM 3.34b / Revenue TTM 33.52b)
Gross Margin = 23.27% ((Revenue TTM 33.52b - Cost of Revenue TTM 25.72b) / Revenue TTM)
Gross Margin QoQ = 23.16% (prev 21.67%)
Tobins Q-Ratio = 1.26 (Enterprise Value 43.70b / Total Assets 34.64b)
Interest Expense / Debt = 0.56% (Interest Expense 31.3m / Debt 5.55b)
Taxrate = 25.47% (203.3m / 798.1m)
NOPAT = 3.25b (EBIT 4.36b * (1 - 25.47%))
Current Ratio = 6.62 (Total Current Assets 30.02b / Total Current Liabilities 4.54b)
Debt / Equity = 0.23 (Debt 5.55b / totalStockholderEquity, last quarter 24.00b)
Debt / EBITDA = 0.68 (Net Debt 3.04b / EBITDA 4.46b)
Debt / FCF = 0.87 (Net Debt 3.04b / FCF TTM 3.48b)
Total Stockholder Equity = 24.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.57% (Net Income 3.34b / Total Assets 34.64b)
RoE = 13.81% (Net Income TTM 3.34b / Total Stockholder Equity 24.14b)
RoCE = 14.68% (EBIT 4.36b / Capital Employed (Equity 24.14b + L.T.Debt 5.55b))
RoIC = 10.67% (NOPAT 3.25b / Invested Capital 30.46b)
WACC = 7.56% (E(40.66b)/V(46.21b) * Re(8.53%) + D(5.55b)/V(46.21b) * Rd(0.56%) * (1-Tc(0.25)))
Discount Rate = 8.53% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -6.53%
[DCF] Terminal Value 80.70% ; FCFF base≈3.23b ; Y1≈3.37b ; Y5≈3.89b
[DCF] Fair Price = 250.0 (EV 75.65b - Net Debt 3.04b = Equity 72.61b / Shares 290.5m; r=7.56% [WACC]; 5y FCF grow 4.56% → 3.0% )
EPS Correlation: -57.15 | EPS CAGR: -16.71% | SUE: 0.26 | # QB: 0
Revenue Correlation: -5.91 | Revenue CAGR: -3.91% | SUE: 0.64 | # QB: 0
EPS next Quarter (2026-06-30): EPS=2.94 | Chg7d=+0.001 | Chg30d=+0.010 | Revisions Net=-13 | Analysts=15
EPS current Year (2026-09-30): EPS=10.53 | Chg7d=+0.001 | Chg30d=-0.017 | Revisions Net=-14 | Growth EPS=-9.0% | Growth Revenue=-0.7%
EPS next Year (2027-09-30): EPS=12.26 | Chg7d=+0.001 | Chg30d=+0.017 | Revisions Net=-12 | Growth EPS=+16.4% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 13 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 0.7% (Discount Rate 8.5% - Earnings Yield 7.9%)
[Growth] Growth Spread = -0.1% (Analyst 0.6% - Implied 0.7%)
External Resources